High Persistent Tumor Mutation Burden Predicts Immunotherapy Response

Article navigation

Research Watch| April 03 2023

Online ISSN: 2159-8290

Print ISSN: 2159-8274

2023

American Association for Cancer Research

Cancer Discov (2023) 13 (4): OF3.

Abstract

Persistent tumor mutation burden varies between cancer types and predicts immunotherapy response.

2023

American Association for Cancer Research

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.